New drug aims to protect pancreas transplants
NCT ID NCT07503834
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests the safety of a drug called Anakinra in 15 people who have just received a pancreas transplant. The goal is to see if blocking a certain immune signal can prevent dangerous blood clots and improve transplant success. Researchers will closely monitor for side effects, especially severe infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anakinra
- What this could lead to
- If safe, this could point toward a way to reduce transplant complications and improve graft survival.
- What could go wrong
- This is a very early, small (15 people), open-label trial with no control group, so results may not be reliable or generalizable. There is also a risk of severe infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC TRANSPLANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Nantes
Nantes, France